NCT00122577View on ClinicalTrials.gov

Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2002

Study Completion Date

July 31, 2004

Conditions
HIV Infections
Interventions
DRUG

Tenofovir

DRUG

Atazanavir

DRUG

Ritonavir

Trial Locations (1)

75015

Service d'Immunologie clinique Hopital Europeen Georges Pompidou, Paris

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00122577 - Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients | Biotech Hunter | Biotech Hunter